Mubadala Bio Adds Two Immunology Therapies to Bioventure Healthcare Portfolio

Oct 7, 2026 · Mubadala

Mubadala Bio says its Bioventure Healthcare subsidiary has launched two immunology therapies, Adalimumab and Ustekinumab. Emirates News Agency reported the announcement on 6 October 2026.

The medicines expand Bioventure Healthcare’s biologics portfolio for chronic immune-mediated conditions. Mubadala Bio said the additions are part of its strategy to widen access to specialised treatments that clinicians can use in long-term disease management.

The announcement concerns the availability of therapies and does not provide medical guidance or confirm a recruitment programme. Patients should rely on qualified healthcare professionals for treatment decisions. Source: Emirates News Agency.

More News from Mubadala

Mubadala

Mubadala, TARAF and Kerzner Plan One&Only Residences on Al Maryah Island

Oct 3, 2026

Mubadala

Mubadala and Aldar Acquire Masdar City Square for AED 918 Million

Sep 17, 2026

Mubadala

Mubadala Agrees to Minority Investment in Luckin Coffee

Sep 13, 2026